Travere Therapeutics Analyst Ratings
Travere Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/25/2023 | 42.1% | Piper Sandler | $19 → $10 | Maintains | Neutral |
| 09/29/2023 | 70.52% | Wedbush | → $12 | Reiterates | Outperform → Outperform |
| 09/22/2023 | 70.52% | Barclays | $31 → $12 | Maintains | Overweight |
| 09/22/2023 | 283.68% | B of A Securities | $41 → $27 | Maintains | Buy |
| 09/22/2023 | 155.78% | Guggenheim | $25 → $18 | Maintains | Buy |
| 09/22/2023 | 98.94% | Evercore ISI Group | $30 → $14 | Maintains | Outperform |
| 09/22/2023 | 155.78% | HC Wainwright & Co. | $32 → $18 | Maintains | Buy |
| 09/22/2023 | 13.68% | Wells Fargo | $24 → $8 | Downgrades | Overweight → Equal-Weight |
| 09/21/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 09/19/2023 | 326.31% | Evercore ISI Group | $30 → $30 | Maintains | Outperform |
| 09/06/2023 | 326.31% | Evercore ISI Group | → $30 | Reinstates | Outperform → Outperform |
| 08/18/2023 | 169.99% | Piper Sandler | $22 → $19 | Maintains | Neutral |
| 08/07/2023 | 354.73% | HC Wainwright & Co. | $35 → $32 | Reiterates | Buy → Buy |
| 07/21/2023 | 269.47% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
| 07/18/2023 | 397.36% | Canaccord Genuity | $37 → $35 | Maintains | Buy |
| 06/21/2023 | 226.83% | Wedbush | → $23 | Reiterates | Outperform → Outperform |
| 06/07/2023 | 212.62% | Piper Sandler | → $22 | Assumes | → Neutral |
| 06/01/2023 | 397.36% | HC Wainwright & Co. | $22 → $35 | Reiterates | → Buy |
| 05/22/2023 | 326.31% | TD Cowen | → $30 | Initiates Coverage On | → Outperform |
| 05/02/2023 | 212.62% | HC Wainwright & Co. | $40 → $22 | Maintains | Buy |
| 05/02/2023 | 454.2% | B of A Securities | $52 → $39 | Maintains | Buy |
| 05/02/2023 | 269.47% | Evercore ISI Group | $36 → $26 | Maintains | Outperform |
| 05/02/2023 | 241.04% | Wells Fargo | $28 → $24 | Maintains | Overweight |
| 05/02/2023 | 226.83% | Guggenheim | $40 → $23 | Maintains | Buy |
| 04/17/2023 | 312.1% | Wedbush | $30 → $29 | Maintains | Outperform |
| 03/01/2023 | 425.78% | Guggenheim | → $37 | Initiates Coverage On | → Buy |
| 02/28/2023 | 496.83% | Canaccord Genuity | $44 → $42 | Maintains | Buy |
| 02/24/2023 | 468.41% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 02/22/2023 | 525.25% | Canaccord Genuity | $40 → $44 | Maintains | Buy |
| 02/21/2023 | 553.67% | Piper Sandler | $42 → $46 | Maintains | Overweight |
| 02/21/2023 | 326.31% | Wedbush | → $30 | Upgrades | Neutral → Outperform |
| 02/21/2023 | 340.52% | Barclays | $37 → $31 | Maintains | Overweight |
| 02/21/2023 | 468.41% | HC Wainwright & Co. | $36 → $40 | Reiterates | → Buy |
| 02/17/2023 | 411.57% | HC Wainwright & Co. | → $36 | Reiterates | → Buy |
| 01/30/2023 | 468.41% | Canaccord Genuity | $33 → $40 | Maintains | Buy |
| 01/11/2023 | 496.83% | Piper Sandler | $38 → $42 | Maintains | Overweight |
| 12/14/2022 | 212.62% | Stifel | → $22 | Initiates Coverage On | → Hold |
| 12/05/2022 | 297.89% | Wells Fargo | → $28 | Initiates Coverage On | → Overweight |
| 10/20/2022 | 439.99% | SVB Leerink | $45 → $38 | Maintains | Outperform |
| 10/17/2022 | 411.57% | HC Wainwright & Co. | $42 → $36 | Maintains | Buy |
| 10/14/2022 | 439.99% | Piper Sandler | $39 → $38 | Maintains | Overweight |
| 08/08/2022 | 496.83% | HC Wainwright & Co. | $46 → $42 | Maintains | Buy |
| 08/05/2022 | 539.46% | SVB Leerink | $42 → $45 | Maintains | Outperform |
| 07/26/2022 | 482.62% | Piper Sandler | $40 → $41 | Maintains | Overweight |
| 07/14/2022 | 496.83% | Canaccord Genuity | → $42 | Assumes | → Buy |
| 05/17/2022 | 553.67% | HC Wainwright & Co. | $45 → $46 | Maintains | Buy |
| 05/06/2022 | 468.41% | Piper Sandler | $42 → $40 | Maintains | Overweight |
| 03/31/2022 | 496.83% | Piper Sandler | → $42 | Initiates Coverage On | → Overweight |
| 02/28/2022 | 539.46% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
| 12/16/2021 | 468.41% | Barclays | $36 → $40 | Maintains | Overweight |
| 12/16/2021 | 496.83% | SVB Leerink | $37 → $42 | Maintains | Outperform |
| 08/17/2021 | 425.78% | SVB Leerink | $27 → $37 | Maintains | Outperform |
| 05/27/2021 | 539.46% | Canaccord Genuity | $48 → $45 | Maintains | Buy |
| 05/26/2021 | 169.99% | Wedbush | → $19 | Downgrades | Outperform → Neutral |
| 05/17/2021 | 582.09% | Canaccord Genuity | $51 → $48 | Maintains | Buy |
| 02/03/2021 | 624.72% | Canaccord Genuity | $28 → $51 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月25日 | 42.1% | 派珀·桑德勒 | $19→$10 | 維護 | 中性 |
| 09/29/2023 | 70.52% | 韋德布什 | →$12 | 重申 | 跑贏→跑贏大盤 |
| 09/22/2023 | 70.52% | 巴克萊 | $31→$12 | 維護 | 超重 |
| 09/22/2023 | 283.68% | B of A證券 | $41→$27 | 維護 | 買 |
| 09/22/2023 | 155.78% | 古根海姆 | $25→$18 | 維護 | 買 |
| 09/22/2023 | 98.94% | Evercore ISI集團 | $30→$14 | 維護 | 跑贏大盤 |
| 09/22/2023 | 155.78% | HC Wainwright公司 | $32→$18 | 維護 | 買 |
| 09/22/2023 | 13.68% | 富國銀行 | $24→$8 | 評級下調 | 超重→等重 |
| 2023年09月21日 | - | 威廉·布萊爾 | 評級下調 | 跑贏→市場表現 | |
| 2023/09/19 | 326.31% | Evercore ISI集團 | $30→$30 | 維護 | 跑贏大盤 |
| 09/06/2023 | 326.31% | Evercore ISI集團 | →$30 | 恢復 | 跑贏→跑贏大盤 |
| 2023年08月18日 | 169.99% | 派珀·桑德勒 | $22→$19 | 維護 | 中性 |
| 08/07/2023 | 354.73% | HC Wainwright公司 | $35→$32 | 重申 | 購買→購買 |
| 07/21/2023 | 269.47% | 摩根大通 | →$26 | 開始承保 | →超重 |
| 07/18/2023 | 397.36% | 卡納科特·格納奇 | $37→$35 | 維護 | 買 |
| 2023年6月21日 | 226.83% | 韋德布什 | →$23 | 重申 | 跑贏→跑贏大盤 |
| 06/07/2023 | 212.62% | 派珀·桑德勒 | →$22 | 假設 | →中性 |
| 06/01/2023 | 397.36% | HC Wainwright公司 | $22→$35 | 重申 | →購買 |
| 2023年05月22日 | 326.31% | TD Cowen | →$30 | 開始承保 | →跑贏大盤 |
| 05/02/2023 | 212.62% | HC Wainwright公司 | $40→$22 | 維護 | 買 |
| 05/02/2023 | 454.2% | B of A證券 | $52→$39 | 維護 | 買 |
| 05/02/2023 | 269.47% | Evercore ISI集團 | $36→$26 | 維護 | 跑贏大盤 |
| 05/02/2023 | 241.04% | 富國銀行 | $28→$24 | 維護 | 超重 |
| 05/02/2023 | 226.83% | 古根海姆 | $40→$23 | 維護 | 買 |
| 04/17/2023 | 312.1% | 韋德布什 | $30→$29 | 維護 | 跑贏大盤 |
| 03/01/2023 | 425.78% | 古根海姆 | →$37 | 開始承保 | →購買 |
| 02/28/2023 | 496.83% | 卡納科特·格納奇 | $44→$42 | 維護 | 買 |
| 02/24/2023 | 468.41% | HC Wainwright公司 | →$40 | 重申 | →購買 |
| 02/22/2023 | 525.25% | 卡納科特·格納奇 | $40→$44 | 維護 | 買 |
| 02/21/2023 | 553.67% | 派珀·桑德勒 | $42→$46 | 維護 | 超重 |
| 02/21/2023 | 326.31% | 韋德布什 | →$30 | 升級 | 中性→表現優異 |
| 02/21/2023 | 340.52% | 巴克萊 | $37→$31 | 維護 | 超重 |
| 02/21/2023 | 468.41% | HC Wainwright公司 | $36→$40 | 重申 | →購買 |
| 02/17/2023 | 411.57% | HC Wainwright公司 | →$36 | 重申 | →購買 |
| 2023年1月30日 | 468.41% | 卡納科特·格納奇 | $33→$40 | 維護 | 買 |
| 2023年1月11日 | 496.83% | 派珀·桑德勒 | $38→$42 | 維護 | 超重 |
| 2022年12月14日 | 212.62% | Stifel | →$22 | 開始承保 | →保留 |
| 12/05/2022 | 297.89% | 富國銀行 | →$28 | 開始承保 | →超重 |
| 10/20/2022 | 439.99% | SVB Leerink | $45→$38 | 維護 | 跑贏大盤 |
| 10/17/2022 | 411.57% | HC Wainwright公司 | $42→$36 | 維護 | 買 |
| 10/14/2022 | 439.99% | 派珀·桑德勒 | $39→$38 | 維護 | 超重 |
| 2022/08/08 | 496.83% | HC Wainwright公司 | $46→$42 | 維護 | 買 |
| 08/05/2022 | 539.46% | SVB Leerink | $42→$45 | 維護 | 跑贏大盤 |
| 07/26/2022 | 482.62% | 派珀·桑德勒 | $40→$41 | 維護 | 超重 |
| 07/14/2022 | 496.83% | 卡納科特·格納奇 | →$42 | 假設 | →購買 |
| 2022/05/17 | 553.67% | HC Wainwright公司 | $45→$46 | 維護 | 買 |
| 05/06/2022 | 468.41% | 派珀·桑德勒 | $42→$40 | 維護 | 超重 |
| 03/31/2022 | 496.83% | 派珀·桑德勒 | →$42 | 開始承保 | →超重 |
| 02/28/2022 | 539.46% | HC Wainwright公司 | →$45 | 開始承保 | →購買 |
| 12/16/2021 | 468.41% | 巴克萊 | $36→$40 | 維護 | 超重 |
| 12/16/2021 | 496.83% | SVB Leerink | $37→$42 | 維護 | 跑贏大盤 |
| 2021/08/17 | 425.78% | SVB Leerink | $27→$37 | 維護 | 跑贏大盤 |
| 2021/05/27 | 539.46% | 卡納科特·格納奇 | $48→$45 | 維護 | 買 |
| 2021/05/26 | 169.99% | 韋德布什 | →$19 | 評級下調 | 跑贏→中性 |
| 2021/05/17 | 582.09% | 卡納科特·格納奇 | $51→$48 | 維護 | 買 |
| 02/03/2021 | 624.72% | 卡納科特·格納奇 | $28→$51 | 維護 | 買 |
What is the target price for Travere Therapeutics (TVTX)?
Travere Treeutics(TVTX)的目標價格是多少？
The latest price target for Travere Therapeutics (NASDAQ: TVTX) was reported by Piper Sandler on October 25, 2023. The analyst firm set a price target for $10.00 expecting TVTX to rise to within 12 months (a possible 42.10% upside). 38 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年10月25日報道了Travere治療公司(納斯達克代碼：TVTX)的最新目標價。這家分析公司將目標價定為10.00美元，預計TVTX將在12個月內上漲(可能上漲42.10%)。去年有38家分析公司公佈了評級。
What is the most recent analyst rating for Travere Therapeutics (TVTX)?
Travere Treeutics(TVTX)的最新分析師評級是什麼？
The latest analyst rating for Travere Therapeutics (NASDAQ: TVTX) was provided by Piper Sandler, and Travere Therapeutics maintained their neutral rating.
派珀·桑德勒對特拉華治療公司(納斯達克股票代碼：TVTX)的最新分析師評級是由派珀·桑德勒提供的，特拉維爾治療公司維持其中性評級。
When is the next analyst rating going to be posted or updated for Travere Therapeutics (TVTX)?
Travere Treeutics(TVTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on October 25, 2023 so you should expect the next rating to be made available sometime around October 25, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Travere Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Travere治療公司的上一次評級是在2023年10月25日提交的，所以你應該預計下一次評級將在2024年10月25日左右的某個時候提供。
Is the Analyst Rating Travere Therapeutics (TVTX) correct?
分析師對Travere Treeutics(TVTX)的評級正確嗎？
While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a maintained with a price target of $19.00 to $10.00. The current price Travere Therapeutics (TVTX) is trading at is $7.04, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Travere Treateutics(TVTX)評級保持不變，目標價在19.00美元至10.00美元之間。Travere Treateutics(TVTX)目前的交易價格為7.04美元，超出了分析師的預測範圍。